Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591553816> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2591553816 endingPage "e13084" @default.
- W2591553816 startingPage "e13084" @default.
- W2591553816 abstract "e13084 Background: Several clinical trials have evaluated the effect of dendritic cell (DC) vaccination in the treatment of melanoma patients but so far the clinical results have been disappointing. In this trial metronomic cyclophosphamide (Cy) and celecoxib have been added to a treatment regimen with DC vaccination and interleukin (IL-) 2 in the intend to overcome immunosuppressive mechanisms. Methods: 28 patients with progressive metastatic melanoma were included in this phase II trial. Vaccines consisted of autologues DCs pulsed with survivin, hTERT and p53 derived peptides (HLA-A2+) or tumor lysate (HLA-A2-). Vaccine no. 1-4 was given weekly, vaccine 5-10 biweekly and monthly vaccines thereafter until disease progression. Concomitantly the patient was treated with IL-2, 2 MIU for five days following each vaccine, Cy 50 mg twice a day every second week and Celecoxib 200 mg daily. Objectives were safety and tolerability, immunological and clinical responses, time to progression (TTP) and overall survival (OS). Results: The treatment was safe and no grade 3 or 4 adverse events were observed. 16 patients (57%) had SD according to RECIST at 1st evaluation and 8 patients had prolonged SD (7-13.7 months). There were no differences in prognostic factors between the patients with SD and progressive disease (PD) at 1st evaluation. Vaccine induced immune responses have been observed and 5 out of 6 patients with increasing immune responses had SD; the 6th patient had prolonged OS (+ 20 months). Despite the use of metronomic Cy blood level of regulatory T cells (Treg) increased during treatment. The median TTP was 4.5 months and the median OS was 9 months. Patients with SD had a median OS at 13.7 months; patients with PD had an OS at 6.0 months (p = 0.02). Conclusions: It seems that a vaccine induced immune response is more common among patients who achieve SD during treatment. When comparing results from a previous trial without Cy we see that the number of patients obtaining SD more than doubled (57% vs. 24%), PFS was prolonged but unfortunately OS did not improve. Notably, metronomic Cy was unable to reduce Treg level." @default.
- W2591553816 created "2017-03-03" @default.
- W2591553816 creator A5017721294 @default.
- W2591553816 creator A5017744060 @default.
- W2591553816 creator A5022552883 @default.
- W2591553816 creator A5031370633 @default.
- W2591553816 creator A5051043977 @default.
- W2591553816 creator A5071158961 @default.
- W2591553816 creator A5074783389 @default.
- W2591553816 creator A5076893524 @default.
- W2591553816 date "2011-05-20" @default.
- W2591553816 modified "2023-09-26" @default.
- W2591553816 title "Melanoma patients treated with dendritic cell vaccination, interleukin-2, and metronomic cyclophosphamide: Results from a phase II trial." @default.
- W2591553816 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e13084" @default.
- W2591553816 hasPublicationYear "2011" @default.
- W2591553816 type Work @default.
- W2591553816 sameAs 2591553816 @default.
- W2591553816 citedByCount "0" @default.
- W2591553816 crossrefType "journal-article" @default.
- W2591553816 hasAuthorship W2591553816A5017721294 @default.
- W2591553816 hasAuthorship W2591553816A5017744060 @default.
- W2591553816 hasAuthorship W2591553816A5022552883 @default.
- W2591553816 hasAuthorship W2591553816A5031370633 @default.
- W2591553816 hasAuthorship W2591553816A5051043977 @default.
- W2591553816 hasAuthorship W2591553816A5071158961 @default.
- W2591553816 hasAuthorship W2591553816A5074783389 @default.
- W2591553816 hasAuthorship W2591553816A5076893524 @default.
- W2591553816 hasConcept C126322002 @default.
- W2591553816 hasConcept C143998085 @default.
- W2591553816 hasConcept C197934379 @default.
- W2591553816 hasConcept C203014093 @default.
- W2591553816 hasConcept C22070199 @default.
- W2591553816 hasConcept C2776694085 @default.
- W2591553816 hasConcept C2776755627 @default.
- W2591553816 hasConcept C2777658100 @default.
- W2591553816 hasConcept C2778375690 @default.
- W2591553816 hasConcept C2781413609 @default.
- W2591553816 hasConcept C502942594 @default.
- W2591553816 hasConcept C535046627 @default.
- W2591553816 hasConcept C71924100 @default.
- W2591553816 hasConcept C8891405 @default.
- W2591553816 hasConcept C90924648 @default.
- W2591553816 hasConceptScore W2591553816C126322002 @default.
- W2591553816 hasConceptScore W2591553816C143998085 @default.
- W2591553816 hasConceptScore W2591553816C197934379 @default.
- W2591553816 hasConceptScore W2591553816C203014093 @default.
- W2591553816 hasConceptScore W2591553816C22070199 @default.
- W2591553816 hasConceptScore W2591553816C2776694085 @default.
- W2591553816 hasConceptScore W2591553816C2776755627 @default.
- W2591553816 hasConceptScore W2591553816C2777658100 @default.
- W2591553816 hasConceptScore W2591553816C2778375690 @default.
- W2591553816 hasConceptScore W2591553816C2781413609 @default.
- W2591553816 hasConceptScore W2591553816C502942594 @default.
- W2591553816 hasConceptScore W2591553816C535046627 @default.
- W2591553816 hasConceptScore W2591553816C71924100 @default.
- W2591553816 hasConceptScore W2591553816C8891405 @default.
- W2591553816 hasConceptScore W2591553816C90924648 @default.
- W2591553816 hasIssue "15_suppl" @default.
- W2591553816 hasLocation W25915538161 @default.
- W2591553816 hasOpenAccess W2591553816 @default.
- W2591553816 hasPrimaryLocation W25915538161 @default.
- W2591553816 hasRelatedWork W1968036257 @default.
- W2591553816 hasRelatedWork W2007986200 @default.
- W2591553816 hasRelatedWork W2019574320 @default.
- W2591553816 hasRelatedWork W2073975292 @default.
- W2591553816 hasRelatedWork W2107697672 @default.
- W2591553816 hasRelatedWork W2137859389 @default.
- W2591553816 hasRelatedWork W2171389860 @default.
- W2591553816 hasRelatedWork W2281121233 @default.
- W2591553816 hasRelatedWork W4206914007 @default.
- W2591553816 hasRelatedWork W4221063257 @default.
- W2591553816 hasVolume "29" @default.
- W2591553816 isParatext "false" @default.
- W2591553816 isRetracted "false" @default.
- W2591553816 magId "2591553816" @default.
- W2591553816 workType "article" @default.